< Back to search
Filter
1

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

for
Relapsed/Refractory Multiple Myeloma
Location: Boston MA, Stony Brook NY, New York NY,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05850234

Phase1, Phase2, Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

for
Multiple Myeloma
Location: Fredericton, Boston MA, Newton MA, Worcester MA,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT06215118

Phase1, Recruiting

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Oklahoma City OK
Sponsor: Sorrento Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05007418

Phase1, Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Boston MA, New York NY, Hackensack NJ, Buffalo NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06121843

Phase1, Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT03761108

Phase1, Phase2, Recruiting

Interested in new multiple sclerosis trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

for
Relapsed or Refractory Multiple Myeloma (RRMM)
Location: Halifax, Boston MA, New York NY, Montreal,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06615479

Phase3, Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

for
Multiple Myeloma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT05776979

Phase2, Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

for
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM),
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT06103838

Phase2, Recruiting

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

for
Multiple Myeloma
Location: Detroit MI, Lansing MI
Sponsor: Barbara Ann Karmanos Cancer Institute

Sex: All

Age: 18+

Code: NCT06107738

Phase2, Recruiting

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

for
Smoldering Multiple Myeloma
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06212323

Recruiting

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

for
Multiple Myeloma
Location: Jacksonville FL, Encinitas CA, Alhambra CA,
Sponsor: Oncotherapeutics

Sex: All

Age: 18+

Code: NCT03110822

Phase1, Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

for
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06083922

Phase2, Recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

for
Multiple Myeloma, Renal Failure
Location: Augusta GA
Sponsor: Augusta University

Sex: All

Age: 18 - 70+

Code: NCT06142396

Early_phase1, Recruiting

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

for
Multiple Myeloma
Location: Boston MA, Durham NC, Chapel Hill NC, Cincinnati OH,
Sponsor: Prolexys Pharmaceuticals

Sex: All

Age: 18+

Code: NCT01695590

Phase1, Phase2, Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

for
Multiple Myeloma, Plasma Cell Disorder
Location: New York NY, Atlanta GA, Houston TX
Sponsor: Heidelberg Pharma AG

Sex: All

Age: 18+

Code: NCT04879043

Phase1, Phase2, Recruiting

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

for
Multiple Myeloma
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT06048250

Phase1, Recruiting

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma

for
Multiple Myeloma, Exercise, Prehabilitation
Location: Edmonton
Sponsor: University of Alberta

Sex: All

Age: 18+

Code: NCT06280924

Recruiting

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

for
Multiple Myeloma
Location: Montreal
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Sex: All

Age: 18+

Code: NCT05530096

Recruiting

End Diagnostic Overshadowing

for
Disabilities Multiple
Location: Chicago IL
Sponsor: Rush University Medical Center

Sex: All

Age: 3 - 70+

Code: NCT06608758

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

for
Multiple Myeloma
Location: Halifax, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT05623020

Phase3, Recruiting